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A new woman-controlled contraceptive vaginal ring:
a global step forward
More than 40 years ago, the development of
contraceptive vaginal rings began, based on the fact that
the vaginal epithelium can absorb steroid hormones and
the capacity of elastomers to release these hormones at
almost constant rates.1 The growing interest in womancontrolled contraceptive methods has supported and
accelerated the process.
The main advantages of contraceptive vaginal
rings are their effectiveness, ease of use, user control,
nearly constant release rate allowing for lower doses
of hormones, greater bioavailability, and good
cycle control compared with oral contraceptives.2
There are two types of contraceptive vaginal ring
on the market—Nuvaring (Merck Sharp & Dohme;
Kenilworth, NJ, USA), which releases etonogestrel and
ethinylestradiol for 1 month, and Progering (Silesia;
Santiago, Chile), which is a 3-month progesteroneonly ring for use during breastfeeding. Both rings are
expensive, require refrigeration, and are not readily
available in low-income and middle-income countries
(LMICs). Therefore, reducing costs and expanding the
availability of contraceptive vaginal rings is important,
as is development of those with longer durations that
do not need refrigeration, which would increase the
contraceptive options for women globally.
In The Lancet Global Health, David Archer and
colleagues3 report the results of two non-randomised,
open-label, single-arm phase 3 trials of a ringshaped, contraceptive vaginal system developed by
the Population Council, which releases a consistent
amount of segesterone acetate and ethinylestradiol
over 1 year of cyclic use and does not require
refrigeration. These trials were done at US and non-US
sites and evaluated the efficacy of the contraceptive
vaginal system and return to menses or pregnancy
after use.3 The results showed the efficacy and safety of
this contraceptive system, with an overall Pearl Index
of 2·98 (95% CI 2·13–4·06) and a contraceptive efficacy
rate of 97·5% on the basis of a life-table analysis. All
participants who were followed up reported return
to menses or pregnancy within 6 months. As this
contraceptive vaginal system is effective for a full
year of cyclic use and does not require refrigeration
www.thelancet.com/lancetgh Vol 7 August 2019

during periods of non-use, this is likely to facilitate
accessibility and help to address a global unmet
contraceptive need.3
Gemzel-Danielson and colleagues4 reported that the
1-year segesterone acetate 150 µg and ethinylestradiol
13 µg daily contraceptive vaginal system represents a
new long-term, user-controlled, and procedure-free
contraceptive option with a safety profile similar to
other combined hormonal contraceptives.4 The new
contraceptive vaginal system is a safe and effective
combined hormonal contraceptive that is under a
woman’s control and was considered acceptable by
women who participated in the clinical trials.3
Addressing the unmet contraceptive need remains
a global high priority, as illustrated by recent reports
assessing progress in meeting contraceptive demands
since the Family Planning 2020 Summit.5,6 Cahill and
colleagues5 reported that between 2012 and 2017
the number of women of reproductive age who were
married or in a union and using modern methods of
contraception increased by 28·8 million, with success
stories including rapid increases in use in Kenya,
Mozambique, Malawi, Lesotho, Sierra Leone, Liberia,
and Chad relative to what was expected in 2012.
However, they also underlined that global levels of
contraceptive prevalence mask the diversity in progress
at the country level.5 Ahmed and colleagues6 showed
that annual percentage increases in contraceptive use
were above the average of 1·4 percentage points needed
to achieve the 2012 Family Planning Summit goal to
provide family planning to an additional 120 million
women by 2020.6,7 However, progress was shown to
be slow in several countries where the annual rate of
change was lower than 1 percentage point, far below the
target needed to achieve the goal.6
Multiple factors play a part in contraceptive use and
need to be addressed. Availability and affordability of a
portfolio of modern contraceptive methods, including
this new birth control option, might help address the
persistent, unmet, global contraceptive need. This new
contraceptive vaginal ring was approved by the US Food
and Drug Administration in August, 2018, and thus
represents the first ring not requiring refrigeration to

Published Online
June 20, 2019
http://dx.doi.org/10.1016/
S2214-109X(19)30289-X
See Articles page e1054

e986

Comment

offer women a whole year of contraceptive protection,
contributing to equity and choice.8
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